Mucinous adenocarcinomas: Poor prognosis in metastatic colorectal cancer

European Journal of Cancer

Volumn 48, Issue 4, 2012, Pages 501-509

  Mekenkamp, Leonie J M ^a   Heesterbeek, Karin J ^a   Koopman, Miriam ^b   Tol, Jolien ^a   Teerenstra, Steven ^a   Venderbosch, Sabine ^a   Punt, Cornelis J A ^a,c   Nagtegaal, Iris D ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Chemotherapy; Metastatic colorectal cancer; Mucinous adenocarcinomas; Prognostic marker; Targeted therapy

Indexed keywords

B RAF KINASE; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; IRINOTECAN; K RAS PROTEIN; LACTATE DEHYDROGENASE; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CLINICAL FEATURE; COLON ADENOCARCINOMA; COLORECTAL CARCINOMA; CONTROLLED STUDY; FEMALE; GENE MUTATION; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; INDEPENDENT VARIABLE; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCINOUS CARCINOMA; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; CLINICAL TRIALS, PHASE III AS TOPIC; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES;

EID: 84857051602     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.12.004     Document Type: Article

References (40)

1. D.A. Symonds, and A.L. Vickery Mucinous carcinoma of the colon and rectum Cancer 37 1976 1891 1900
2. M. Melis, J. Hernandez, and E.M. Siegel Gene expression profiling of colorectal mucinous adenocarcinomas Dis Colon Rectum 53 2010 936 943
3. J.M. Chiang, C.Y. Yeh, and C.R. Changchien Mucinous adenocarcinoma showing different clinicopathological and molecular characteristics in relation to different colorectal cancer subgroups Int J Colorectal Dis 25 2010 941 947
4. T. Nozoe, H. Anai, S. Nasu, and K. Sugimachi Clinicopathological characteristics of mucinous carcinoma of the colon and rectum J Surg Oncol 75 2000 103 107
5. W. Song, S.J. Wu, and Y.L. He Clinicopathologic features and survival of patients with colorectal mucinous, signet-ring cell or non-mucinous adenocarcinoma: experience at an institution in southern China Chin Med J (Engl) 122 2009 1486 1491
6. F.V. Negri, A. Wotherspoon, and D. Cunningham Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer Ann Oncol 16 2005 1305 1310 (Pubitemid 41158475)
7. V. Catalano, F. Loupakis, and F. Graziano Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy Br J Cancer 100 2009 881 887
8. M.H. Chew, S.A. Yeo, and Z.P. Ng Critical analysis of mucin and signet ring cell as prognostic factors in an Asian population of 2,764 sporadic colorectal cancers Int J Colorectal Dis 25 2010 1221 1229
9. C. Hanski Is mucinous carcinoma of the colorectum a distinct genetic entity? Br J Cancer 72 1995 1350 1356 (Pubitemid 26002642)
10. S. Ogino, M. Brahmandam, and M. Cantor Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component Mod Pathol 19 2006 59 68 (Pubitemid 43250979)
11. W.Q. Li, K. Kawakami, and A. Ruszkiewicz BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status Mol Cancer 5 2006 2
12. C.A. Purdie, and J. Piris Histopathological grade, mucinous differentiation and DNA ploidy in relation to prognosis in colorectal carcinoma Histopathology 36 2000 121 126 (Pubitemid 30113973)
13. Y. Kazama, T. Watanabe, and T. Kanazawa Mucinous carcinomas of the colon and rectum show higher rates of microsatellite instability and lower rates of chromosomal instability: a study matched for T classification and tumour location Cancer 103 2005 2023 2029 (Pubitemid 40605108)
14. H. Tanaka, G. Deng, and K. Matsuzaki BRAF mutation, CpG island methylator phenotype and microsatellite instability occur more frequently and concordantly in mucinous than non-mucinous colorectal cancer Int J Cancer 118 2006 2765 2771 (Pubitemid 43673355)
15. V.N. Papadopoulos, A. Michalopoulos, and S. Netta Prognostic significance of mucinous component in colorectal carcinoma Tech Coloproctol 8 Suppl. 1 2004 s123 s125
16. S. Leopoldo, B. Lorena, and A. Cinzia Two subtypes of mucinous adenocarcinoma of the colorectum: clinicopathological and genetic features Ann Surg Oncol 15 2008 1429 1439
17. J. Tol, I.D. Nagtegaal, and C.J. Punt BRAF mutation in metastatic colorectal cancer N Engl J Med 361 2009 98 99
18. M. Koopman, N.F. Antonini, and J. Douma Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial Lancet 370 2007 135 142 (Pubitemid 47042893)
19. J. Tol, M. Koopman, and A. Cats Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer N Engl J Med 360 2009 563 572
20. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
21. World Health Organization. International histological classification of malignant tumours. 2nd ed. Berlin: Springer-Verlag; 1988.
22. L.H. Sobin, and I.D. Fleming TNM classification of malignant tumours, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer Cancer 80 1997 1803 1804
23. M. Koopman, G.A. Kortman, and L. Mekenkamp Deficient mismatch repair system in patients with sporadic advanced colorectal cancer Br J Cancer 100 2009 266 273
24. L.I. Overbeek, C.M. Kets, and K.M. Hebeda Patients with an unexplained microsatellite instable tumour have a low risk of familial cancer Br J Cancer 96 2007 1605 1612 (Pubitemid 46762954)
25. J. Tol, J.R. Dijkstra, and M.E. Vink-Borger High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue J Cell Mol Med 14 2010 2122 2131
26. J. Tol, J.R. Dijkstra, and M. Klomp Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab Eur J Cancer 46 2010 1997 2009
27. J.P. Mecklin, P. Sipponen, and H.J. Jarvinen Histopathology of colorectal carcinomas and adenomas in cancer family syndrome Dis Colon Rectum 29 1986 849 853 (Pubitemid 17208885)
28. L. Messerini, F. Vitelli, and L.R. De Vitis Microsatellite instability in sporadic mucinous colorectal carcinomas: relationship to clinico-pathological variables J Pathol 182 1997 380 384 (Pubitemid 27317201)
29. H. Kim, J. Jen, B. Vogelstein, and S.R. Hamilton Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences Am J Pathol 145 1994 148 156 (Pubitemid 24217493)
30. G.A. Song, G. Deng, and I. Bell Mucinous carcinomas of the colorectum have distinct molecular genetic characteristics Int J Oncol 26 2005 745 750
31. H. Zhang, S. Evertsson, and X. Sun Clinicopathological and genetic characteristics of mucinous carcinomas in the colorectum Int J Oncol 14 1999 1057 1061
32. C.J. Punt, and J. Tol More is less - combining targeted therapies in metastatic colorectal cancer Nat Rev Clin Oncol 6 2009 731 733
33. C.M. Ribic, D.J. Sargent, and M.J. Moore Tumour microsatellite- instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer N Engl J Med 349 2003 247 257 (Pubitemid 36859476)
34. F.A. Sinicrope, N.R. Foster, and S.N. Thibodeau DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy J Natl Cancer Inst 103 2011 863 875
35. S.C. Glasgow, J. Yu, and L.P. Carvalho Unfavourable expression of pharmacologic markers in mucinous colorectal cancer Br J Cancer 92 2005 259 264 (Pubitemid 40343138)
36. M. Koopman, S. Venderbosch, and H. van Tinteren Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study Eur J Cancer 45 2009 1999 2006
37. M. Komatsu, S. Jepson, M.E. Arango, C.A. Carothers Carraway, and K.L. Carraway Muc4/sialomucin complex, an intramembrane modulator of ErbB2/HER2/Neu, potentiates primary tumour growth and suppresses apoptosis in a xenotransplanted tumour Oncogene 20 2001 461 470 (Pubitemid 32158226)
38. S.E. Baldus, S.P. Monig, and F.G. Hanisch Comparative evaluation of the prognostic value of MUC1, MUC2, sialyl-Lewis(a) and sialyl-Lewis(x) antigens in colorectal adenocarcinoma Histopathology 40 2002 440 449 (Pubitemid 34535444)
39. E. Leteurtre, V. Gouyer, and K. Rousseau Differential mucin expression in colon carcinoma HT-29 clones with variable resistance to 5-fluorouracil and methotrexate Biol Cell 96 2004 145 151 (Pubitemid 38391197)
40. S. Venderbosch, J.H. de Wilt, and S. Teerenstra Prognostic value of resection of primary tumour in patients with stage IV colorectal cancer: retrospective analysis of two randomized studies and a review of the literature Ann Surg Oncol 18 2011 3252 3260